5 results on '"London N.R."'
Search Results
2. Assessment of Factors Associated with Internal Carotid Injury in Expanded Endoscopic Endonasal Skull Base Surgery
- Author
-
Christos Georgalas, Davide Locatelli, Garni Barkhoudarian, Ernesto Pasquini, Abdulaziz AlQahtani, Jacques J. Morcos, Nyall R. London, Chester Griffiths, Roy R. Casiano, Daniel F. Kelly, Hussam Elbosraty, Diego Mazzatenta, Georgio Frank, Narayanan Janakiram, Paolo Castelnuovo, Aaron A. Cohen-Gadol, Aldo Cassol Stamm, Ricardo L. Carrau, Piero Nicolai, Daniel M. Prevedello, Alqahtani A., London N.R., Castelnuovo P., Locatelli D., Stamm A., Cohen-Gadol A.A., Elbosraty H., Casiano R., Morcos J., Pasquini E., Frank G., Mazzatenta D., Barkhoudarian G., Griffiths C., Kelly D., Georgalas C., Janakiram N., Nicolai P., Prevedello D.M., and Carrau R.L.
- Subjects
Male ,Operating Rooms ,medicine.medical_specialty ,MEDLINE ,Carotid Artery, Internal, Dissection ,Neurosurgical Procedure ,Tertiary care ,Skull Base Neoplasms ,Neurosurgical Procedures ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Retrospective Studie ,medicine.artery ,Humans ,Medicine ,030223 otorhinolaryngology ,Pathological ,Retrospective Studies ,Original Investigation ,Skull Base ,Base of skull ,medicine.diagnostic_test ,business.industry ,Incidence (epidemiology) ,Risk Factor ,Endoscopy ,Middle Aged ,Surgery ,Otorhinolaryngology ,Operating Room ,Facility Design and Construction ,Skull base surgery ,Female ,Clinical Competence ,Internal carotid artery ,business ,030217 neurology & neurosurgery ,Carotid Artery, Internal ,Human - Abstract
Importance Injury to the internal carotid artery (ICA) during endoscopic endonasal skull base surgery does not typically occur as an isolated circumstance but often is the result of multiple factors. Objective To assess the factors associated with ICA injury in an effort to reduce its occurrence. Design, Setting, and Participants This quality improvement study used a multicenter root cause analysis of ICA injuries sustained during endoscopic endonasal skull base surgery performed at 11 tertiary care centers across 4 continents (North America, South America, Europe, and Asia) from January 1, 1993, to December 31, 2018. A fishbone model was built to facilitate the root cause analysis. Patients who underwent an expanded endoscopic endonasal approach that carried a substantial potential risk of an ICA injury were included in the analysis. A questionnaire was completed by surgeons at the centers to assess relevant human, patient, process, technique, instrument, and environmental factors associated with the injury. Main Outcomes and Measures Root cause analysis of demographic, human, patient, process, technique, instrument, and environmental factors as well as mortality and morbidity data. Results Twenty-eight cases of ICA injury occurred during 7160 expanded endoscopic endonasal approach procedures (incidence of 0.4%). The mean age of the patients was 49 years, with a female to male predominance ratio of 1.8:1 (18 women to 10 men). Anatomical (23 [82%]), pathological (15 [54%]), and surgical resection (26 [93%]) factors were most frequently reported. The surgeon’s mental or physical well-being was reported as inadequate in 4 cases (14%). Suboptimal imaging was reported in 6 cases (21%). The surgeon’s experience level was not associated with ICA injury. The ICA injury was associated with use of powered or sharp instruments in 20 cases (71%), and use of new instruments or technology in 7 cases (25%). Two patients (7%) died in the operating room, and 3 (11%) were alive with neurological deficits. Overall, patient-related factors were the most frequently reported risk factors (in 27 of 28 cases [96%]). Factors associated with ICA injury catalyzed a list of preventive recommendations. Conclusions and Relevance This study found that human factors were associated with intraoperative ICA injuries; however, they were usually accompanied by other deficiencies. These findings suggest that identifying risk factors is crucial for preventing such injuries. Preoperative planning and minimizing the potential for ICA injury also appear to be essential.
- Published
- 2020
3. Teasing the Immune System to Repair the Heart.
- Author
-
Epstein JA, Rosenthal N, and Feldman AM
- Subjects
- Animals, Disease Models, Animal, Heart Failure therapy, Immune System, Mice, Reperfusion Injury immunology, Zymosan therapeutic use, Cell- and Tissue-Based Therapy, Heart Failure immunology, Leukocytes, Mononuclear transplantation, Mesenchymal Stem Cell Transplantation, Reperfusion Injury therapy
- Published
- 2020
- Full Text
- View/download PDF
4. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
- Author
-
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, and Moreau P
- Subjects
- Aged, Antibodies, Monoclonal adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Disease-Free Survival, Drug Resistance, Neoplasm, Humans, Kaplan-Meier Estimate, Lenalidomide, Middle Aged, Multiple Myeloma mortality, Recurrence, Thalidomide administration & dosage, Antibodies, Monoclonal administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Dexamethasone administration & dosage, Multiple Myeloma drug therapy, Thalidomide analogs & derivatives
- Abstract
Background: Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma., Methods: In this phase 3 trial, we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group). The primary end point was progression-free survival., Results: At a median follow-up of 13.5 months in a protocol-specified interim analysis, 169 events of disease progression or death were observed (in 53 of 286 patients [18.5%] in the daratumumab group vs. 116 of 283 [41.0%] in the control group; hazard ratio, 0.37; 95% confidence interval [CI], 0.27 to 0.52; P<0.001 by stratified log-rank test). The Kaplan-Meier rate of progression-free survival at 12 months was 83.2% (95% CI, 78.3 to 87.2) in the daratumumab group, as compared with 60.1% (95% CI, 54.0 to 65.7) in the control group. A significantly higher rate of overall response was observed in the daratumumab group than in the control group (92.9% vs. 76.4%, P<0.001), as was a higher rate of complete response or better (43.1% vs. 19.2%, P<0.001). In the daratumumab group, 22.4% of the patients had results below the threshold for minimal residual disease (1 tumor cell per 10
5 white cells), as compared with 4.6% of those in the control group (P<0.001); results below the threshold for minimal residual disease were associated with improved outcomes. The most common adverse events of grade 3 or 4 during treatment were neutropenia (in 51.9% of the patients in the daratumumab group vs. 37.0% of those in the control group), thrombocytopenia (in 12.7% vs. 13.5%), and anemia (in 12.4% vs. 19.6%). Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2., Conclusions: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy. (Funded by Janssen Research and Development; POLLUX ClinicalTrials.gov number, NCT02076009 .).- Published
- 2016
- Full Text
- View/download PDF
5. Gene-panel sequencing and the prediction of breast-cancer risk.
- Author
-
Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, Devilee P, Meindl A, Couch FJ, Southey M, Goldgar DE, Evans DG, Chenevix-Trench G, Rahman N, Robson M, Domchek SM, and Foulkes WD
- Subjects
- Breast Neoplasms diagnosis, Centers for Disease Control and Prevention, U.S., Female, Genes, BRCA1, Genes, BRCA2, Genotyping Techniques, Heterozygote, Humans, Risk, United States, Breast Neoplasms genetics, Genetic Predisposition to Disease, Genetic Testing standards, Genetic Variation, Guidelines as Topic, Sequence Analysis, DNA
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.